Olr709 inhibitors are a specialized category of chemical compounds known for their ability to specifically target and modulate the activity of the Olr709 receptor, a member of the olfactory receptor family. These receptors, typically found in the olfactory epithelium, are integral to the complex processes of odor detection and signal transduction. Olr709 receptors belong to the G-protein coupled receptor (GPCR) superfamily, which is characterized by their seven transmembrane alpha-helical structures. Upon binding of an appropriate ligand, these receptors undergo conformational changes that activate intracellular G-proteins, initiating a cascade of downstream signaling events. Inhibitors of Olr709 can therefore modulate the initial stages of olfactory signal transduction by preventing the binding of natural ligands or by stabilizing the receptor in an inactive conformation.
The study and development of Olr709 inhibitors involve intricate chemical design and synthesis, often requiring a detailed understanding of receptor-ligand interactions at the molecular level. These inhibitors can be classified based on their structural features, such as small molecules, peptides, or even engineered proteins, each designed to achieve high specificity and affinity for the Olr709 receptor. Advanced techniques such as X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, and molecular docking simulations play crucial roles in elucidating the binding modes and structural conformations of these inhibitors. Furthermore, functional assays and electrophysiological studies are employed to assess the efficacy and potency of these compounds in modulating olfactory receptor activity. The insights gained from these studies not only advance our fundamental understanding of olfactory receptor function but also contribute to the broader field of chemical biology, where selective receptor modulation is a key area of research.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic antagonist, might modulate GPCR activity affecting Olr709. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $124.00 $240.00 $530.00 $999.00 $1530.00 | 2 | |
Beta-adrenergic antagonist with alpha-1 blocking activity, potentially influencing Olr709 signaling. | ||||||
Yohimbine hydrochloride | 65-19-0 | sc-204412 sc-204412A sc-204412B | 1 g 5 g 25 g | $51.00 $171.00 $530.00 | 2 | |
Alpha-2 adrenergic receptor antagonist, could affect GPCR signaling pathways related to Olr709. | ||||||
Labetalol | 36894-69-6 | sc-484723 | 50 mg | $180.00 | ||
Combined alpha and beta blocker, might indirectly affect GPCR pathways including Olr709. | ||||||
Pindolol | 13523-86-9 | sc-204847 sc-204847A | 100 mg 1 g | $194.00 $760.00 | ||
Beta-adrenergic antagonist, could influence GPCR-mediated signaling pathways related to Olr709. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Beta-adrenergic agonist, could indirectly affect Olr709 through GPCR modulation. | ||||||
Atropine | 51-55-8 | sc-252392 | 5 g | $204.00 | 2 | |
Muscarinic acetylcholine receptor antagonist, might influence GPCR signaling pathways including Olr709. | ||||||
Salmeterol | 89365-50-4 | sc-224277 sc-224277A | 10 mg 50 mg | $186.00 $562.00 | 1 | |
Beta-2 adrenergic agonist, potentially affecting GPCR pathways related to Olr709. | ||||||
Alprenolol | 13655-52-2 | sc-507469 | 50 mg | $130.00 | ||
Beta blocker, could indirectly influence GPCR signaling pathways including Olr709. | ||||||